Table 5.
mRNA expression of TLRs in patient group and control subjects.
| IPF | CTD-IP | Sarcoidosis | Controls | P value | |
|---|---|---|---|---|---|
| TLR-2 | 9.75 ± 7.54 | 4.04 ± 3.53 | 599.9 ± 597.7 | 1.72 ± 1.63 | NS |
| TLR-3 | 0.007 ± 0.005 | 2.03 ± 2 | 0.038 ± 0.037 | 0.0014 ± 0.0008 | p1:0.001 p4:0.002 p5:0.05 |
| TLR-4 | 2.34 ± 1.61 | 1.35 ± 1.12 | 20.98 ± 19.3 | 12.37 ± 12.24 | NS |
| TLR-7 | 5.06 ± 4.12 | 12.92 ± 10.25 | 29 ± 26.81 | 1.5 ± 1.35 | p3:0.05 |
| TLR-8 | 11.14 ± 7.89 | 14.5 ± 11.65 | 679.33 ± 672.34 | 8.67 ± 8.51 | NS |
| TLR-9 | 3.1 ± 2.51 | 1.54 ± 0.94 | 213.52 ± 211.95 | 0.58 ± 0.53 | p6:0.05 |
Values are expressed as means ± SEM (standard error of the mean). Mann-Whitney U test; P < 0.05 is considered statistically significant. NS, not significant.
p1: P value between IPF and CTD-IPs, p2: P value between IPF and sarcoidosis, p3: P value between IPF and control, p4: P value between CTD-IP and sarcoidosis, p5: P value between CTD-IP and control, p6: P value between sarcoidosis and control.